Rani Therapeutics Holdings Inc
ranitherapeutics.comRani Therapeutics Holdings Inc (NASDAQ: RANI) is a clinical-stage biotherapeutics company developing oral drug delivery technology designed to replace injectable biologics. The company does not yet generate product revenue. Its disclosed revenue model centers on license and evaluation agreements with pharmaceutical partners, under which Rani licenses its platform technology. CEO Talat Imran leads the company, with Mir Imran serving as Chairman of the Board. Svai Sanford is Chief Financial Officer. The company files as a smaller reporting company with the SEC, with its 10-K for the fiscal year ended December 31, 2025 filed March 26, 2026. Rani competes against other biotherapeutics and pharmaceutical companies developing alternative drug delivery or injectable biologic platforms. Regulatory approval from the FDA is required before any product candidate can be commercialized, and reimbursement from government and private payors will be required for commercial success.
Products & Services
Oral drug delivery platform technology (the RaniPill) designed to enable oral administration of biologic therapies that are otherwise injectable. Product candidates are in clinical development. Specific pipeline candidates are not detailed in the provided filing excerpts.
Revenue Model
License and evaluation agreements with pharmaceutical partners. No product revenue disclosed in the filing excerpts provided. Pre-commercial stage as of the fiscal year ended December 31, 2025.
Customers & Markets
Pharmaceutical and biotherapeutic company partners as licensees. End patients are those requiring biologic therapies. Reimbursement from government payors (Medicare, Medicaid) and private health insurers is identified as material to future commercial success.
Geographic Exposure
Primarily United States regulatory and commercial focus. Clinical trials conducted in Australia. Data processing activities in Europe and the UK noted in the filing.
Financial Snapshot
Loading...
